Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,225
datasets available to search
ShareScore release 0.9.0
Dataset results
5,225 results for “moderation”
Transcriptome profiles of moderate dysplasia in oral mucosa associated with malignant conversion
GEO Series GSE72627. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Autologous adipose-derived cells transiently moderate inflammation and fibrogenesis in early renal ischemia reperfusion injury
GEO Series GSE139318. Rattus norvegicus. 1 samples. Type: Expression profiling by high throughput sequencing.
very moderate exercise training; variations in stress and toxicity gene expression in rat hearts.
GEO Series GSE3904. Mus musculus; Rattus norvegicus. 6 samples. Type: Expression profiling by array.
Dataset related to article "Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity."
<p>OBJECTIVE:</p> <p>Prostate cancer represents the second most common malignancy in the world and majority of patients have diagnosis of localized disease. The aim of the present study was to compare two cohorts of patients treated with moderate hypofractionation (MHRT) or stereotactic body radiation therapy (SBRT).</p> <p>METHODS:</p> <p>We included patients treated between 2010 and 2015. Inclusion criteria were: adenocarcinoma of the prostate; class risks low or intermediate; WHO performance status 0-2. We evaluated rectal, gastrointestinal toxicity and genitourinary. Measures of outcome were biochemical disease-free survival and overall survival. Propensity score was used to approximate the balance in covariates.</p> <p>RESULTS:</p> <p>209 patients were included, treated with MHRT (<em>n</em> = 109) or SBRT (<em>n</em> = 100). Median follow-up time was 37.4 months. Rates of biochemical disease-free survival at 1- and 3 years were 100 and 95%, respectively. There was no significant difference between the two groups (<em>p</em> = 0.868). Rates of overall survival at 1- and 3 years were 100 and 97.1%, respectively with no differences between the two groups (<em>p</em> = 0.312). After propensity scoring matching, no differences were observed in terms of acute and late rectal and gastrointestinal toxicity. While mild genitourinary side-effects were more common in SBRT group (45.5% <em>vs</em> 19.5 %), Grade 2 and 3 toxicity was increased after MHRT (11.7% <em>vs</em> 2.6 %; <em>p</em> = 0.029).</p> <p>CONCLUSIONS:</p> <p>Moderate hypofractionation and SBRT are two effective and safe options for the treatment of low- and intermediate-risk prostate cancer. The analysis showed no difference in terms of disease's control and survival but increased moderate and severe toxicity after MHRT.</p> <p>ADVANCES IN KNOWLEDGE:</p> <p>Moderate hypofractionation and SBRT are comparable in terms of efficacy while moderate and severe toxicity is more common in the first one.</p>
The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: the moderating role of health engagement
<p>Magon A, Arrigoni C, Graffigna G, Barello S, Moia M, Palareti G, Caruso R. The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: the moderating role of health engagement. Hum Vaccin Immunother. 2021 Oct 13:1-6. doi: 10.1080/21645515.2021.1984123. Epub ahead of print. PMID: 34643478.</p> <p>Abstract</p> <p>Assessing vaccine hesitancy and its determinants is pivotal to optimize vaccine acceptance in anticoagulated patients, given that this population has been described to have a higher risk of severe COVID-19-related complications. This study assessed the moderator role of patients' health engagement on the relationship between health literacy and vaccine hesitancy. A web-based survey was performed in Italy during the first wave (June-August 2020) and the second wave (October 2020-March 2021) of the COVID-19 pandemic, enrolling 288 patients. The rates of vaccine hesitancy reported during the first pandemic wave were 38.4% and 30.8% during the second wave (when a vaccine was available) (<em>p</em> = .164). A moderation analysis was performed to assess the role of health engagement in influencing the relationship from health literacy to vaccine hesitancy. Patients' health engagement enhanced the effects of health literacy on decreasing vaccine hesitancy (<em>p</em> < .001), suggesting that co-construction strategies for communicative action are pivotal.</p>
Breaking Good: Coping as a Moderator on the Self-Leadership - Student Stress Relationship
<p>Paper, which examined the relationship between self-leadership and stress with coping as a moderator. </p>
Determination of China Farmers' Stock Market Investment Intention: Moderating Role of Financial Literacy
Open the record for dataset details and reuse information.
Corporate ESG Performance, Green Innovation, and Financial Performance: The Moderating Role of Financial Risk
Open the record for dataset details and reuse information.
Data set The Determinants of Perceived Risk: A Moderating Role of investor Sophistication
Open the record for dataset details and reuse information.
Dataset related to article "Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)"
<p>This record contains raw data related to article “Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)"</p> <p> </p> <p>Abstract:</p> <p>Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.</p>
Raw data of the publication: Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data (Int J Cardiol . 2023 Jan 15;371:273-277. doi: 10.1016/j.ijcard.2022.09.030. Epub 2022 Sep 15)
<p><strong>Background: </strong>The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin-angiotensin-aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation.</p> <p><strong>Objectives: </strong>Aim of the study was to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF optimally treated patients.</p> <p><strong>Methods and results: </strong>We retrospectively analyzed MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) database, with median follow-up of 4.2 [IQR 1.9-7.5] years. Data on K<sup>+</sup> levels were available in 7087 cases. Patients with K<sup>+</sup> plasma level ≥ 5.6 mEq/L and < 4 mEq/L were excluded. Remaining patients were categorized into normal >4 and < 5 mEq/L (n = 4826, 68%) and moderately high ≥5.0 and ≤ 5.5 mEq/L (n = 496, 7%) K<sup>+</sup>. Then patients were matched by propensity score in 484 couplets of patients. MECKI score value was 7% [IQR 3.1-14.1%] and 7.3% [IQR 3.4-15%] (p = 0.678) in patients with normal and moderately high K<sup>+</sup> values while cardiovascular mortality events at two years follow-up were 41 (4.2%) and 33 (3.4%) (p = 0.333) in each group respectively.</p> <p><strong>Conclusions: </strong>Moderate hyperkalemia does not influence patients' outcome in a large cohort of ambulatory HFrEF patients.</p>
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy
<p>Abstract</p> <p><strong>Background: </strong>Immunosuppressive therapy of Graves' orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed. In previous studies, rituximab (RTX) has been shown to be effective in inactivating moderate-to-severe GO when used early in the disease, but its optimal dosage has never been studied in randomized clinical trials. Aim of this study was to compare the efficacy and safety of different doses of RTX, based on a <em>post-hoc</em> analysis of two open label studies and one prospective trial randomized to IVGC.</p> <p><strong>Methods: </strong>of 40 patients (35 women, 5 men), with active moderate-to-severe GO treated with RTX, 14 received a single dose of 100 mg (Group 1), 15 a single dose of 500 mg (Group 2) and 11 two 1000 mg doses, administered one week apart (Group 3). Thyroid function, TSH-receptor antibodies (TRAb) and peripheral CD19+ cells were measured. Primary endpoint was disease inactivation, measured as a decrease of the Clinical Activity Score (CAS) of at least two points. Secondary endpoints were improvement of proptosis, diplopia, quality of life and safety.</p> <p><strong>Results: </strong>Baseline CAS decreased significantly in all groups (P<0.0001), independently of GO duration or whether patients had newly occurring or relapsing GO after IVGC. Proptosis did not significantly change. There was an inverse correlation between the Gorman score for diplopia and RTX dose (P<0.01). The appearance score of the GO-QoL improved in Group 1 (P=0.015), and the visual function score, in Group 2 (P=0.04). A reduction of serum TRAb was observed in Group 1 (P=0.002) and Group 2 (P<0.0002), but not in Group 3. CD19+ cell decreased in all groups (P<0.01), independently of the dose.</p> <p><strong>Conclusions: </strong>We studied the optimal dosage of RTX in the treatment of active moderate-to-severe GO. In this analysis, we considered the efficacy of RTX in inactivating GO, in changing its natural course, its effect on disease severity and on the patients' quality of life. Based on our clinical findings, and balancing the cost of therapy, a single 500 mg dose regimen is suggested in the majority of patients.</p>
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV itolizumab Trial: RESURRECT
<p>Datasets pertaining to the manuscript, Original Research, entitled “<strong>RE</strong>covery and <strong>SUR</strong>vival of patients with moderate to severe acute <strong>RE</strong>spiratory distress syndrome (ARDS) due to <strong>C</strong>OVID-19: a multicentre, single-arm, Phase IV Itolizumab <strong>T</strong>rial: <strong>RESURRECT</strong>” are submitted here. </p>
Mild to moderate post-COVID- 19 alters markers of lymphocyte activation, exhaustion, and immunometabolic responses that can be partially associated by physical activity level— an observational sub-analysis fit- COVID study
<p>Physical activity status seems to be protective against the severe form of SARS-CoV-2, reducing risk of hospitalization and worsened clinical outcome. However, the impact of physical activity after mild-to-moderate COVID-19 episode on immune and metabolic profiles is unknown. Therefore, this study aimed to evaluate if physical activity is associated with systemic and<br> cellular immunometabolic responses, in young adults after mild-to-moderate COVID-19 infection. Patients previously infected with COVID-19 and healthy controls were recruited for this cross-sectional observational study.</p>
Expression data in lung tissue from moderate COPD patients, healthy smokers and nonsmokers
GEO Series GSE37768. Homo sapiens. 38 samples. Type: Expression profiling by array.
Clinical evaluation of an over-the-counter hearing aid (TEO First®) in elderly patients suffering of mild to moderate hearing loss
<p>de-identifed dataset concerning Current Controlled Trials NCT01815788</p>
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
<p>Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared with those who had been previously treated with only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in “real-life” clinical practice could differ from pivotal clinical trials data.</p>
INFLUENCE OF CHEST WALL CONFORMATION ON SPIROMETRY PARAMETERS AND OUTCOME IN MILD TO MODERATE IDIOPATHIC PULMONARY FIBROSIS
<p>Extrinsic causes of restrictive lung syndrome in idiopathic pulmonary fibrosis (IPF) patients have been poorly investigated. We aimed to investigate the influence of the anterior chest wall deformity, noninvasively assessed by modified Haller index (MHI), on spirometry parameters and outcome in a consecutive population of patients with mild-to-moderate IPF.</p> <p>60 consecutive IPF patients (73.8 ± 6.6 yrs, 45 males) were included in this retrospective study. All patients underwent physical examination, spirometry, blood tests, conventional transthoracic echocardiography and MHI assessment (chest transverse diameter over the distance between sternum and spine) at basal evaluation. During follow-up, we evaluated the composite endpoint of 1) pulmonary or cardiovascular hospitalizations; 2) all-cause mortality.</p> <p>IPF patients with concave-shaped chest wall (MHI >2.5) (36.7% of total) and those with normal chest shape (MHI ≤2.5) (63.3%) were separetely analyzed. In comparison to IPF patients with MHI ≤2.5, those with MHI >2.5: were less likely to be men and smokers; had a more severe restrictive pattern; had significantly smaller cardiac chamber dimensions and significantly higher systolic pulmonary artery pressure (51.9±15.1 vs 42.4±14.3 mmHg, p=0.02). Mean follow-up time was 2.5±1.4 yrs. During follow-up, 13 deaths and 16 pulmonary or cardiovascular hospitalizations were detected. At multivariate Cox regression analysis, concave-shaped chest wall (MHI>2.5) (HR 4.55, 95%CI 1.02-20.4), increased C-reactive protein (HR 1.68, 95%CI 1.08-2.61) and absence of beta-blocker therapy (HR 0.13, 95%CI 0.01-0.26) were independently associated to the investigated outcome.</p> <p>MHI assessment and implementation may help the clinician to identify, among IPF patients, those with poorer prognosis over a medium-term follow-up.</p>
INCREMENTAL PROGNOSTIC VALUE OF ARTERIAL ELASTANCE IN MILD-TO-MODERATE IDIOPATHIC PULMONARY FIBROSIS
<p><strong>PURPOSE: </strong>Previous reports suggested that poor pulmonary function was associated with increased arterial elastance (Ea) in patients with chronic obstructive pulmonary disease and systemic sclerosis. The mechanisms connecting pulmonary function and Ea have not yet been accurately studied in patients with idiopathic pulmonary fibrosis (IPF). The present study was designed to assess Ea in IPF patients without chronic severe pulmonary hypertension and to determine its prognostic role over a medium-term follow-up.</p> <p><strong>METHODS: </strong>This retrospective study included 60 consecutive patients with mild-to-moderate IPF (73.8±6.6 yrs, 75% males) and 60 controls matched by age, sex and cardiovascular risk factors. All patients underwent physical examination, spirometry, blood tests, modified Haller index (MHI, chest transverse diameter over the distance between sternum and spine) assessment, conventional transthoracic echocardiography implemented with speckle tracking analysis of left atrial positive global strain (LA-GSA+) and finally carotid Doppler ultrasonography, at basal evaluation. The effective arterial elastance index (EaI) was calculated as the ratio of end-systolic pressure to stroke volume index. During follow-up period, we evaluated the composite endpoint of 1) pulmonary or cardiovascular hospitalizations; 2) all-cause mortality.</p> <p><strong>RESULTS: </strong>At baseline, EaI was significantly higher in IPF patients than controls (4.1±1.3 vs 3.5±1.0 mmHg/ml/m<sup>2</sup>, p=0.01). EaI was strongly correlated to the following variables: C-reactive protein (CRP) (r=0.86), forced vital capacity (FVC) (r=-0.91), E/e’ ratio (r=0.91), LA-GSA+ (r=-0.92), common carotid artery-cross sectional area (CCA-CSA) (r=0.89) and MHI (r=0.86), in IPF patients. Mean follow-up time was 2.4±1.3 yrs. During follow-up, 12 patients died and 17 were hospitalized due to major adverse clinical events. At univariate Cox analysis, CRP (HR 1.51, 95%CI 1.25-1.82), FVC (HR 0.88, 95%CI 0.85-0.91), LA-GSA+ (HR 0.85, 95%CI 0.77-0.94), CCA-CSA (HR 1.12, 95%CI 1.03-1.22) and EaI (HR 2.43, 95%CI 1.75-3.37) were significantly associated with outcome. At multivariate Cox analysis, only EaI (HR 1.60, 95%CI 1.03-2.50) retained statistical significance. An EaI ≥4 mmHg/ml/m<sup>2 </sup>showed 100% sensitivity and 99.4% specificity for predicting outcome (AUC=0.98).</p> <p><strong>CONCLUSIONS: </strong>In patients with mild-to-moderate IPF, an EaI ≥4 mmHg/ml/m<sup>2 </sup>is a negative prognostic factor over a medium-term follow-up.</p>
data set related to article Parenting practices moderate the link between attention to the eyes and callous unemotional traits in children with Disruptive Behavior Disorder: An eye-tracking study
<p>This record contains raw data related to article Parenting practices moderate the link between attention to the eyes and callous unemotional traits in children with Disruptive Behavior Disorder: An eye-tracking study</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.